Newron Pharmaceuticals SpA - Asset Resilience Ratio
Newron Pharmaceuticals SpA (NWRN) has an Asset Resilience Ratio of 41.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Newron Pharmaceuticals SpA short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Newron Pharmaceuticals SpA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NWRN total asset value.
Liquid Assets Composition Over Time
This chart breaks down Newron Pharmaceuticals SpA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Newron Pharmaceuticals SpA to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF16.68 Million | 41.67% |
| Total Liquid Assets | CHF16.68 Million | 41.67% |
Asset Resilience Insights
- Very High Liquidity: Newron Pharmaceuticals SpA maintains exceptional liquid asset reserves at 41.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Newron Pharmaceuticals SpA Industry Peers by Asset Resilience Ratio
Compare Newron Pharmaceuticals SpA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Newron Pharmaceuticals SpA (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Newron Pharmaceuticals SpA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.67% | CHF16.68 Million ≈ $21.08 Million |
CHF40.02 Million ≈ $50.60 Million |
+37.14pp |
| 2024-12-31 | 4.53% | CHF2.89 Million ≈ $3.66 Million |
CHF63.91 Million ≈ $80.80 Million |
-19.68pp |
| 2023-12-31 | 24.21% | CHF6.26 Million ≈ $7.92 Million |
CHF25.87 Million ≈ $32.70 Million |
-0.93pp |
| 2022-12-31 | 25.14% | CHF9.35 Million ≈ $11.82 Million |
CHF37.20 Million ≈ $47.02 Million |
+6.17pp |
| 2021-12-31 | 18.97% | CHF9.57 Million ≈ $12.11 Million |
CHF50.49 Million ≈ $63.83 Million |
-16.26pp |
| 2020-12-31 | 35.23% | CHF18.04 Million ≈ $22.80 Million |
CHF51.20 Million ≈ $64.73 Million |
+6.85pp |
| 2019-12-31 | 28.38% | CHF17.11 Million ≈ $21.63 Million |
CHF60.29 Million ≈ $76.22 Million |
+1.33pp |
| 2018-12-31 | 27.05% | CHF16.23 Million ≈ $20.52 Million |
CHF60.00 Million ≈ $75.85 Million |
+0.43pp |
| 2017-12-31 | 26.62% | CHF19.44 Million ≈ $24.58 Million |
CHF73.02 Million ≈ $92.32 Million |
+20.40pp |
| 2016-12-31 | 6.22% | CHF3.52 Million ≈ $4.45 Million |
CHF56.59 Million ≈ $71.55 Million |
-4.87pp |
| 2015-12-31 | 11.09% | CHF4.92 Million ≈ $6.22 Million |
CHF44.38 Million ≈ $56.11 Million |
-7.65pp |
| 2014-12-31 | 18.74% | CHF6.95 Million ≈ $8.78 Million |
CHF37.07 Million ≈ $46.87 Million |
+1.48pp |
| 2013-12-31 | 17.26% | CHF5.46 Million ≈ $6.90 Million |
CHF31.62 Million ≈ $39.97 Million |
+9.10pp |
| 2012-12-31 | 8.16% | CHF3.64 Million ≈ $4.60 Million |
CHF44.65 Million ≈ $56.45 Million |
+4.30pp |
| 2009-12-31 | 3.85% | CHF1.60 Million ≈ $2.03 Million |
CHF41.68 Million ≈ $52.69 Million |
-- |
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more